Ascletis Pharma Inc
HKEX:1672
Income Statement
Earnings Waterfall
Ascletis Pharma Inc
Revenue
|
56.6m
CNY
|
Cost of Revenue
|
-30.6m
CNY
|
Gross Profit
|
26m
CNY
|
Operating Expenses
|
-328.2m
CNY
|
Operating Income
|
-302.2m
CNY
|
Other Expenses
|
157.5m
CNY
|
Net Income
|
-144.7m
CNY
|
Income Statement
Ascletis Pharma Inc
Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|
Revenue | ||||||
Revenue |
77
N/A
|
79
+2%
|
54
-31%
|
62
+15%
|
57
-9%
|
|
Gross Profit | ||||||
Cost of Revenue |
(38)
|
(12)
|
(79)
|
(73)
|
(31)
|
|
Gross Profit |
39
N/A
|
66
+69%
|
(25)
N/A
|
(10)
+58%
|
26
N/A
|
|
Operating Income | ||||||
Operating Expenses |
(245)
|
(222)
|
(375)
|
(210)
|
(328)
|
|
Selling, General & Administrative |
(51)
|
(48)
|
(52)
|
(50)
|
(116)
|
|
Research & Development |
(213)
|
(258)
|
(267)
|
(241)
|
(217)
|
|
Other Operating Expenses |
19
|
84
|
(55)
|
81
|
5
|
|
Operating Income |
(206)
N/A
|
(156)
+24%
|
(399)
-157%
|
(221)
+45%
|
(302)
-37%
|
|
Pre-Tax Income | ||||||
Interest Income Expense |
7
|
(21)
|
85
|
(23)
|
97
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
61
|
|
Pre-Tax Income |
(199)
N/A
|
(176)
+11%
|
(315)
-79%
|
(243)
+23%
|
(145)
+41%
|
|
Net Income | ||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(199)
|
(176)
|
(315)
|
(243)
|
(145)
|
|
Net Income (Common) |
(199)
N/A
|
(176)
+11%
|
(315)
-79%
|
(243)
+23%
|
(145)
+41%
|
|
EPS (Diluted) |
-0.18
N/A
|
-0.16
+11%
|
-0.29
-81%
|
-0.22
+24%
|
-0.13
+41%
|